Anti-Human CD52 (Alemtuzumab)

Antibody Details

Product Details

Reactivity Species

Human/Rhesus Monkey/Cynomolgus Monkey

Host Species

Human

Expression Host

HEK-293

FC Effector Activity

Active

Immunogen

Human lymphocytes.

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

≤ 1.0 EU/mg as determined by the LAL method

Purity

> 95% by SDS-PAGE and HPLC

Formulation

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pathogen Testing

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Storage and Handling

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Regulatory Status

Research Use Only (RUO). Non-Therapeutic.

Country of Origin

USA

Shipping

Next Day 2-8°C

RRID

AB_2893935

Applications and Recommended Usage?
Quality Tested by Leinco

FC The suggested concentration for Alemtuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 10⁶ cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.

Other Applications Reported In Literature ?

IHC FFPE (Formalin-fixed paraffin-embedded tissue)
IHC FF (Fresh Frozen)
FA
WB
ELISA

Additional Reported Applications For Relevant Conjugates ?

CyTOF®

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Alemtuzumab. Clone Campath-1H recognizes human CD52. This product is for research use only.

Antigen Distribution

CD52 is primarily expressed on the surface of mature lymphocytes. Additionally, CD52 is present on most lymphoid derived malignancies. However, variable expression on Myeloma cells should be noted.

Background

Clone Campath-1H is a monoclonal antibody that specifically binds to CD52, a protein present on the surface of mature lymphocytes. However, this protein is not present on the stem cells that generated these lymphocytes. Alemtuzumab is targets and destroys mature lymphocytes containing CD-52, and is used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. Anti-Human CD52 (Alemtuzumab) utilizes the same variable regions from the therapeutic antibody Alemtuzumab making it ideal for research projects.

Antigen Details

Protein

CD52

PubMed

CD52

NCBI Gene Bank ID

1043

UniProt.org

Information on Uniprot.org

Technical Protocols